# Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting

> **NCT00932529** · PHASE4 · COMPLETED · sponsor: **University of Bergen** · enrollment: 226 (actual)

## Conditions studied

- Psychotic Disorders

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Quetiapine
- **DRUG:** Risperidone
- **DRUG:** Ziprasidone

## Key facts

- **NCT ID:** NCT00932529
- **Lead sponsor:** University of Bergen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2010-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932529, "Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00932529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*